Advertisement

Topics

Ethris Enters Strategic Collaboration with AstraZeneca and MedImmune to Develop mRNA Therapies for Respiratory Diseases

02:00 EDT 21 Aug 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Ethris GmbH, a leader in mRNA-based therapeutics with specific expertise in pulmonary disease, today announced a five-year strategic research collaboration with AstraZeneca and its global biologics research and development arm, ...

Other Sources for this Article

Ethris GmbH
Ilse Huebner-Seibl
+49-(0)89-8955-788 10
info@ethris.com
or
Media requests:
MacDougall Biomedical Communications
Mario Brkulj or Joanne Tudorica
Phone: +49 175 501 05 75 or +49 (0) 89 2424 3494
mbrkulj@macbiocom.com

NEXT ARTICLE

More From BioPortfolio on "Ethris Enters Strategic Collaboration with AstraZeneca and MedImmune to Develop mRNA Therapies for Respiratory Diseases"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...